Changing utilization of Stavudine (d4T) in HIV-positive people in 2006-2013 in the EuroSIDA study

HIV Medicine

Volumn 16, Issue 9, 2015, Pages 533-543

  Podlekareva, D ^a   Grint, D ^b   Karpov, I ^c   Vassilenko, A ^c   Rakmanova, A ^d   Mansinho, K ^e   Chentsova, N ^f   Kravchenko, E ^f   Zeltina, I ^g,bk   Losso, M ^h   Parczewski, M ⁱ   Lundgren, Jd ^a   Mocroft, A ^b,cz   Kirk, O ^a   Kundro, M ^h   Vetter, N ^j   Zangerle, R ^k   Mitsura, V M ^l   Suetnov, O ^m   Clumeck, N ⁿ   De Wit, S ⁿ   Delforge, M ⁿ   Florence, E ^o   Vandekerckhove, L ^p   Hadziosmanovic, V ^q   Kostov, K ^r   Begovac, J ^s   Machala, L ^t   Jilich, D ^t   Sedlacek, D ^u   Nielsen, J ^v   Kronborg, G ^t   Benfield, T ^t   Larsen, M ^t   Gerstoft, J ^w   Katzenstein, T ^t   Hansen, A B E ^t   Skinhoj P ^t   Pedersen, C ^x   Ostergaard, L ^y   Dragsted, U B ^z   Nielsen, L N ^aa   Zilmer, K ^ab   Jelena Smidt, ^ac   Ristola, M ^ad   Katlama, C ^ae   Viard, J P ^af   Girard, P M ^ag   Vanhems, P ^ah   Pradier, C ^ai   Dabis, F ^aj   Neau, D ^aj   Duvivier, C ^ak   Rockstroh, J ^al   Schmidt, ^am   van Lunzen, J ^an   Degen, O ^an   Stellbrink, H J ^ao   Bickel, M ^ap   Goethe, J W ^ap   Bogner, J ^aq   Fatkenheuer G ^ar   Kosmidis, J ^as   Gargalianos, P ^as   Xylomenos, G ^as   Perdios, J ^as   Sambatakou, H ^at   Banhegyi, D ^au   Gottfredsson, M ^av   Mulcahy, F ^aw   Yust, I ^ax   Turner, D ^ax   Burke, M ^ax   Pollack, S ^ay   Hassoun, G ^ay   Elinav, H ^az   Haouzi, M ^az   D'Arminio Monforte, A ^ba   Esposito, R ^bb   Mazeu, I ^bb   Mussini, C ^bb   Arici, C ^bc   Pristera, R ^bd   Mazzotta, F ^be   Gabbuti, A ^be   Vullo, V ^bf   Lichtner, M ^bf   Chirianni, A ^bg   Montesarchio, E ^bg   Gargiulo, M ^bg   D'Offizi, G ^bh   Taibi, C ^bh   Antinori, A ^bh   Lazzarin, A ^bi   Castagna, A ^bi   Gianotti, N ^bi   Galli, M ^bj   Ridolfo, A ^bj   Rozentale, B ^bk   Chaplinskas, S ^bl   Staub, T ^bm   Hemmer, R ^bm   Reiss, P ^bn   Ormaasen, V ^bo   Maeland, A ^bo   Bruun, J ^bo   Knysz, B ^bp   Gasiorowski, J ^bp   Horban, A ^bq   Bakowska, E ^bq   Grzeszczuk, A ^br   Flisiak, R ^br   A Boron Kaczmarska, ⁱ   Pynka, M ⁱ   Beniowski, M ^bs   Mularska, E ^bs   Trocha, H ^bt   Jablonowska, E ^bu   Malolepsza, E ^bu   Wojcik, K ^bu   Doroana, M ^bv   Caldeira, L ^bv   Maltez, F ^bw   Duiculescu, D ^bx   Rakhmanova, A ^by   Buzunova, S ^bz   Khromova, I ^ca   Kuzovatova, E ^cb   Jevtovic, D ^cc   Mokras M ^cd   Stanekova D ^cd   Tomazic, J ^ce   Gonzalez Lahoz J ^cf   Soriano, V ^cf   Labarga, P ^cf   Moreno, S ^cg   Rodriguez, J M ^cg   Clotet, B ^ch   Jou, A ^ch   Paredes, R ^ch   Tural, C ^ch   Puig, J ^ch   Bravo, I ^ch   Gatell, J M ^ci   Miro J M ^ci   Domingo, P ^cj   Gutierrez, M ^cj   Mateo, G ^cj   Sambeat, M A ^cj   Medrano, J ^ck   Blaxhult, A ^cl   Flamholc, L ^cm   Thalme, A ^cn   Sonnerborg, A ^cn   Ledergerber, B ^co   Weber, R ^co   Francioli, P ^cp   Cavassini, M ^cp   Hirschel, B ^cq   Boffi, E ^cq   Furrer, H ^cr   Battegay, M ^cs   Elzi, L ^cs   Vernazza, P ^ct   Frolov, V ^cu   Kutsyna, G ^cu   Servitskiy, S ^cv   Kuznetsova, A ^cw   Kyselyova, G ^cx   Gazzard, B ^cy   Johnson, A M ^b   Simons, E ^b   Phillips, A ^cz   Johnson, M A ^cz   Orkin, C ^da   Weber, J ^db   Scullard, G ^db   Fisher, M ^dc   Leen, C ^dd   more..

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c BELARUSIAN STATE MEDICAL UNIVERSITY   (Belarus)

^d Medical Academy Botkin Hospital   (Russian Federation)

^e HOSPITAL EGAS MONIZ   (Portugal)

^f Kiev Centre for AIDS   (Ukraine)

^g RIGA EAST UNIVERSITY HOSPITAL   (Latvia)

^h HOSPITAL RAMOS MEJÍA   (Argentina)

ⁱ POMERANIAN MEDICAL UNIVERSITY   (Poland)

^j Pulmologisches Zentrum   (Austria)

^k INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^l GOMEL STATE MEDICAL UNIVERSITY   (Belarus)

^m Regional AIDS Centre   (Belarus)

ⁿ SAINT PIERRE UNIVERSITY HOSPITAL   (Belgium)

^o INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^p GHENT UNIVERSITY HOSPITAL   (Belgium)

^q Klinicki Centar Univerziteta Sarajevo   (Bosnia and Herzegovina)

^r Infectious Diseases Hospital   (Bulgaria)

^s Croatia   (Croatia)

^t UNIVERSITY HOSPITAL BULOVKA   (Czech Republic)

^u CHARLES UNIVERSITY   (Czech Republic)

^v HVIDOVRE HOSPITAL   (Denmark)

^w University of Copenhagen   (Denmark)

^x ODENSE UNIVERSITY HOSPITAL   (Denmark)

^y AARHUS UNIVERSITY HOSPITAL   (Denmark)

^z ROSKILDE HOSPITAL   (Denmark)

^aa HILLERØD HOSPITAL   (Denmark)

^ab WEST TALLINN CENTRAL HOSPITAL   (Estonia)

^ac Nakkusosakond Siseklinik   (Estonia)

^ad HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^ae PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^af HÔTEL DIEU   (France)

^ag HÔPITAL SAINT ANTOINE   (France)

^ah UNIVERSITÉ LYON 1   (France)

^ai CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^aj INSERM   (France)

^ak HÔPITAL NECKER ENFANTS MALADES   (France)

^al UNIVERSITY HOSPITAL BONN   (Germany)

^am HANNOVER MEDICAL SCHOOL   (Germany)

^an UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^ao IPM Study Center   (Germany)

^ap UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^aq LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^ar UNIVERSITY OF COLOGNE   (Germany)

^as IASO GENERAL HOSPITAL   (Greece)

^at Ippokration Genereal Hospital   (Greece)

^au Szent Laszlo Hospital   (Hungary)

^av LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

^aw ST JAMES S HOSPITAL   (Ireland)

^ax TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^ay RAMBAM MEDICAL CENTER   (Israel)

^az HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^ba Istituto di Clinica Malattie Infettive e Tropicale   (Italy)

^bb UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^bc OSPEDALI RIUNITI   (Italy)

^bd OSPEDALE CA FONCELLO   (Italy)

^be SANTA MARIA ANNUNZIATA HOSPITAL   (Italy)

^bf SAPIENZA UNIVERSITY OF ROME   (Italy)

^bg MONALDI HOSPITAL   (Italy)

^bh NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^bi SAN RAFFAELE HOSPITAL   (Italy)

^bj UNIVERSITY OF MILAN   (Italy)

^bk Infectology Centre of Latvia   (Latvia)

^bl Lithuanian AIDS Centre   (Lithuania)

^bm Centre Hospitalier   (Luxembourg)

^bn ACADEMIC MEDICAL CENTER   (Netherlands)

^bo ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^bp WROCLAW MEDICAL UNIVERSITY   (Poland)

^bq SP ZOZ Wojewodzki Szpital Zakazny Centrum Diagnostyki i Terapii AIDS Warszawa   (Poland)

^br MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^bs Osrodek Diagnostyki i Terapii AIDS   (Poland)

^bt MEDICAL UNIVERSITY OF GDANSK   (Poland)

^bu Wojewodzki Szpital Specjalistyczny   (Poland)

^bv HOSPITAL DE SANTA MARIA   (Portugal)

^bw HOSPITAL CURRY CABRAL   (Portugal)

^bx VICTOR BABES NATIONAL INSTITUTE OF PATHOLOGY   (Romania)

^by St Petersburg Munic Geriatric Ctr   (Russian Federation)

^bz Nizhny Novgorod Center for AIDS and Infectious Diseases Prevention and Control   (Russian Federation)

^ca Centre for HIV AIDS and Infectious Diseases   (Russian Federation)

^cb Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing   (Russian Federation)

^cc Institute for Infectious and Tropical Diseases   (Serbia)

^cd Derer 's University Hospital Slovakia   (Slovakia)

^ce UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^cf HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^cg HOSPITAL RAMÓN Y CAJAL   (Spain)

^ch HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^ci HOSPITAL CLÍNIC   (Spain)

^cj Hospital Sant Pau   (Spain)

^ck HOSPITAL TXAGORRITXU   (Spain)

^cl STOCKHOLM SÖDER HOSPITAL   (Sweden)

^cm LUND UNIVERSITY HOSPITAL   (Sweden)

^cn KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^co UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^cp LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^cq GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^cr UNIVERSITY OF BERN   (Switzerland)

^cs UNIVERSITY HOSPITAL BASEL   (Switzerland)

^ct CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^cu Lugansk State Medical University   (Ukraine)

^cv Odessa Region AIDS Centre   (Ukraine)

^cw KHARKIV NATIONAL MEDICAL UNIVERSITY   (Ukraine)

^cx Crimean Republican AIDS centre   (Ukraine)

^cy CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^cz ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^da ROYAL LONDON HOSPITAL   (United Kingdom)

^db IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^dc ROYAL SUSSEX COUNTY HOSPITAL   (United Kingdom)

^dd WESTERN GENERAL HOSPITAL   (United Kingdom)

more..

Author keywords

Combination antiretroviral therapy; Europe; EuroSIDA; HIV; Stavudine utilization

Indexed keywords

ANTIRETROVIRUS AGENT; STAVUDINE; VIRUS RNA; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; ARTICLE; DRUG TREATMENT FAILURE; DRUG UTILIZATION; DRUG WITHDRAWAL; DYSLIPIDEMIA; EASTERN EUROPE; EUROPE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); NEUROTOXICITY; PREVALENCE; PRIORITY JOURNAL; SIDE EFFECT; ADVERSE EFFECTS; CLINICAL TRIAL; DRUG EFFECTS; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; MIDDLE AGED; MULTICENTER STUDY; PROSPECTIVE STUDY; REGRESSION ANALYSIS;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; EUROPE; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; REGRESSION ANALYSIS; RNA, VIRAL; STAVUDINE;

EID: 84940788331     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/hiv.12254     Document Type: Article

References (38)

1. Spruance SL, Pavia AT, Mellors JW etal. Clinical efficacy of monotherapy with stavudine compared with zidovudine in HIV-infected, zidovudine-experienced patients. A randomized, double-blind, controlled trial. Bristol-Myers Squibb Stavudine/019 Study Group. Ann Intern Med 1997; 126: 355-363.
2. Squires KE, Gulick R, Tebas P etal. A comparison of stavudine plus lamivudine versus zidovudine plus lamivudine in combination with indinavir in antiretroviral naive individuals with HIV infection: selection of thymidine analog regimen therapy (START I). AIDS 2000; 14: 1591-1600.
3. Mallon PW, Miller J, Cooper DA, Carr A. Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy. AIDS 2003; 17: 971-979.
4. Joly V, Flandre P, Meiffredy V etal. Increased risk of lipoatrophy under stavudine in HIV-1-infected patients: results of a substudy from a comparative trial. AIDS 2002; 16: 2447-2454.
5. Walker UA, Setzer B, Venhoff N. Increased long-term mitochondrial toxicity in combinations of nucleoside analogue reverse-transcriptase inhibitors. AIDS 2002; 16: 2165-2173.
6. Kakuda TN, Brundage RC, Anderson PL, Fletcher CV. Nucleoside reverse transcriptase inhibitor-induced mitochondrial toxicity as an etiology for lipodystrophy. AIDS 1999; 13: 2311-2312.
7. Brinkman K, Smeitink JA, Romijn JA, Reiss P. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet 1999; 354: 1112-1115.
8. Brinkman K, ter Hofstede HJ, Burger DM, Smeitink JA, Koopmans PP. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. AIDS 1998; 12: 1735-1744.
9. Hurst M, Noble S. Stavudine: an update of its use in the treatment of HIV infection. Drugs 1999; 58: 919-949.
10. Simpson DM, Tagliati M. Nucleoside analogue-associated peripheral neuropathy in human immunodeficiency virus infection. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 9: 153-161.
11. Menezes CN, Duarte R, Dickens C etal. The early effects of stavudine compared with tenofovir on adipocyte gene expression, mitochondrial DNA copy number and metabolic parameters in South African HIV-infected patients: a randomized trial. HIV Med 2013; 14: 217-225.
12. Menezes CN, Maskew M, Sanne I, Crowther NJ, Raal FJ. A longitudinal study of stavudine-associated toxicities in a large cohort of South African HIV infected subjects. BMC Infect Dis 2011; 11: 244.
13. Chene G, Angelini E, Cotte L etal. Role of long-term nucleoside-analogue therapy in lipodystrophy and metabolic disorders in human immunodeficiency virus-infected patients. Clin Infect Dis 2002; 34: 649-657.
14. Llibre JM, Domingo P, Palacios R etal. Sustained improvement of dyslipidaemia in HAART-treated patients replacing stavudine with tenofovir. AIDS 2006; 20: 1407-1414.
15. Gallant JE, Staszewski S, Pozniak AL. Efficacy and safety of tenofovir df vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004; 292: 191-201.
16. Panel on Clinical Practices for Treatment of HIV Infection. Guidelines for the use of antiretroviral agents in HIV, infected adults and adolescents. March 23, 2004, Department of Health and Human Services. 2004. Available at: http://aidsinfo.nih.gov/contentfiles/adultandadolescentgl03232004003.pdf (accessed 15 March 2015).
17. World Health Organization. Addendum to 2006 WHO Guidelines on Antiretroviral Therapy for HIV Infection in Adults and Adolescents. Available at http://www.who.int/hiv/art/ARTadultsaddendum.pdf (accessed 15 March 2015).
18. World Health Organization. WHO Rapid Advice: Antiretroviral therapy for HIV Infection in Adults and Adolescents. WHO, 2009. Available at http://www.who.int/hiv/pub/arv/rapid_advice:art.pdf (accessed 15 March 2015).
19. European Medicines Agency. Assessment report. Zerit (Stavudine): procedure No: EMEA/H/C/000110/R/0079. 2011. Available at http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/000110/WC500106749.pdf (accessed 15 March 2015).
20. European Medicines Agency. Questions and answers on the review of Zerit (stavudine): outcome of renewal procedure. EMA/127094/2011. EMEA/H/C/000110/R/79. 2011. Available at http://www.ema.europa.eu/docs/en_GB/document_library/Medicine_QA/human/000110/WC500102227.pdf (accessed 15 March 2015).
21. Mocroft A, Ledergerber B, Katlama C etal. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 2003; 362: 22-29.
22. Podlekareva D, Bannister W, Mocroft A etal. The EuroSIDA study: regional differences in the HIV-1 epidemic and treatment response to antiretroviral therapy among HIV-infected patients across Europe-a review of published results. Cent Eur J Public Health 2008; 16: 99-105.
23. Centers for Disease Control. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 1992/41 (RR-17).
24. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 2014. Department of Health and Human Services. Available at: http://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. (accessed 15 March 2015).
25. EACS. European Guidelines for treatment of HIV-infected adults in Europe. Version 7.1. November 2014. Available at: http://www.eacsociety.org/files/guidelines_english_71_141204.pdf (accessed 15 March 2015).
26. Jimenez-Nacher I, Garcia B, Barreiro P etal. Trends in the prescription of antiretroviral drugs and impact on plasma HIV-RNA measurements. J Antimicrob Chemother 2008; 62: 816-822.
27. Smit M, Smit C, Geerlings S etal. Changes in first-line cART regimens and short-term clinical outcome between 1996 and 2010 in The Netherlands. PLoS ONE 2013; 8: e76071.
28. UNAIDS. AIDS epidemic update: 2005. Available at: http://www.unaids.org/epi/2005/ (accessed 15 March 2015).
29. Brennan AT, Maskew M, Ive P etal. Increases in regimen durability associated with the introduction of tenofovir at a large public-sector clinic in Johannesburg, South Africa. J Int AIDS Soc 2013; 16: 18794.
30. Geng EH, Hunt PW, Diero LO etal. Trends in the clinical characteristics of HIV-infected patients initiating antiretroviral therapy in Kenya, Uganda and Tanzania between 2002 and 2009. J Int AIDS Soc 2011; 14: 46.
31. Franzeck FC, Letang E, Mwaigomole G etal. cART prescription trends in a prospective HIV cohort in rural Tanzania from 2007 to 2011. BMC Infect Dis 2014; 14: 90.
32. Kruk A, Bannister W, Podlekareva DN etal. Tuberculosis among HIV-positive patients across Europe: changes over time and risk factors. AIDS 2011; 25: 1505-1513.
33. Breen RA, Lipman MC, Johnson MA. Increased incidence of peripheral neuropathy with co-administration of stavudine and isoniazid in HIV-infected individuals. AIDS 2000; 14: 615.
34. Ryom L, Sabin C, Reiss P etal. Association Between Dideoxynucleoside Analogues (d-drugs) and End-Stage Liver Disease (ESLD). Conference On Retroviruses And Opportunistic Infections, CROI, March 3-6 2014, Boston, USA. Abstract N 787. Available at: http://www.chip.dk/portals/0/files/CROI_2014_DAD_ESLD_Ryom_Wed22.00.pdf (accessed 15 March 2015).
35. Bannister WP, Kirk O, Gatell JM etal. Regional changes over time in initial virologic response rates to combination antiretroviral therapy across Europe. J Acquir Immune Defic Syndr 2006; 42: 229-237.
36. Mocroft A, Horban A, Clotet B etal. Regional differences in the risk of triple class failure in European patients starting combination antiretroviral therapy after 1 January 1999. HIV Med 2008; 9: 41-46.
37. Podlekareva DN, Reekie J, Mocroft A etal. Benchmarking HIV health care: from individual patient care to health care evaluation. An example from the EuroSIDA study. BMC Infect Dis 2012; 12: 229.
38. Maskew M, Westreich D, Fox MP, Maotoe T, Sanne IM. Effectiveness and safety of 30mg versus 40mg stavudine regimens: a cohort study among HIV infected adults initiating HAART in South Africa. J Int AIDS Soc 2012; 15(1): 13.